PCSK9 medicine soon after heart attack to protect the heart
Treatments studied
Part of Heart & circulation clinical trials.
This trial studies whether starting a PCSK9-blocking medicine early after a specific type of heart attack can improve heart outcomes. You may be eligible if you have a STEMI heart attack soon, are planning a procedure to open the blocked artery, and meet safety and pregnancy criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 80 years old
- Have a STEMI heart attack within the past 24 hours
- Plan to have PPCI (an urgent procedure to open the blocked artery)
- Sign the informed consent form
- Not be allergic to PCSK9 inhibitors
- Not have major liver/kidney failure or very limited life expectancy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether starting a cholesterol-lowering injection (a PCSK9 inhibitor) early after a heart attack can slow or shrink the buildup of plaque in other heart arteries that are not the one that was stented. If you have two other arteries with mild blockages, this treatment might help prevent future heart problems.
This trial studies whether starting a cholesterol-lowering medicine called a PCSK9 inhibitor early after a heart attack can improve heart health and outcomes. It focuses on people who had a recent heart-artery procedure to fix the blockage in the left anterior descending (LAD) artery.
This trial tests whether giving a powerful cholesterol-lowering drug (PCSK9 inhibitor) very early after a heart attack can help prevent further heart problems. It is for people who have had a recent heart attack and have blockages in more than one heart artery.
This trial tests whether quickly starting an aggressive cholesterol-lowering treatment after a stroke improves recovery. It is for people who are about to have a procedure to remove a large blood clot from their brain.
This study tests whether adding a PCSK9 inhibitor (a newer cholesterol-lowering shot) to standard treatment can reduce heart risks in people who have certain high-risk plaque features seen on a CT scan of their heart arteries.
This trial tests whether giving a strong cholesterol-lowering treatment within 24 hours of a heart attack (during the procedure to open blocked arteries, called PCI) can reduce the risk of further heart problems. It aims to see if a rapid drop in cholesterol helps patients recover better.
Hear when a new Acute Myocardial Infarction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.